Steven Bernstein
Analyst · the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this conference call.
It is now my pleasure to introduce your host, Mr. Stanton Sloane, President and CEO. Sir, you may begin
Thank you, Stan, and good afternoon. For the 6 months ending October 31, 2020, consolidated revenue was $26.9 million, up 25% compared to $21.6 million for the same period of the prior fiscal year.
The components of revenue are as follows. Revenue from commercial and U.S. Government satellite programs was $14.2 million compared to $9.4 million for the same period of the prior fiscal year and accounted for approximately 53% of consolidated revenue compared to 44% for the same period of the prior fiscal year.
Revenues on satellite payload contracts are recognized primarily under the percentage of completion method and are recorded only in the FEI-New York segment.
Revenues from nonspace, U.S. Government and DOD customers, which are recorded in both the FEI-New York and FEI-Zyfer segments, were $10.9 million compared to $9 million in the same period of the prior fiscal year and accounted for approximately 40% of consolidated revenue compared to 42% for the prior fiscal year.
Other commercial and industrial revenues were $1.9 million compared to $3.2 million in the prior fiscal year. Intersegment revenues are eliminated in consolidation.
For the 6-month period ending October 31, 2020, gross margin and gross margin rate increased significantly as compared to the same period in fiscal year '20. The increase in gross margin and gross margin rate was due to several programs identified in prior periods that had higher engineering costs incurred during the development phase and which are now completed or are near completion.
For the 6 months ending October 31, 2020, and '19, selling and administrative expenses were approximately 27% and 22%, respectively, of consolidated revenue. The increase in SG&A expenses is mainly due to an increase in professional fees relating to litigation for which we expect insurance reimbursement for a portion of the legal fees and some additional insurance costs.
R&D expense for the 6 months ending October 31, 2020, and 2019 decreased $2.2 million to -- from $3.7 million, a decrease of $1.5 million and were 8% and 17% of consolidated revenue. The company's R&D expense decreased year-over-year as previous R&D efforts have ended and turned into production. However, the company plans to continue to invest in R&D to keep its products state of the art.
For the 6 months ending October 31, 2020, the company reported an operating loss of $119,000 compared to $5.7 million in the prior year. Operating loss has made a significant improvement from the same period of the prior fiscal year and reflects improvements in revenue, gross margin and gross margin rate. Based upon our bookings and backlog, we are expecting the improving trend to continue.
Other income consists primarily of investment income derived from the company's holdings of marketable securities. For the 6-month period ending October 31, 2020, investment income includes $105,000 dividend from Morion compared to $125,000 dividend from Morion in the same period in fiscal '20. This yields pretax income of approximately $93,000 compared to a pretax loss of approximately $5.5 million for the prior year.
For the 6 months ending October 31, 2020, the company recorded a tax provision of $25,000 compared to $29,000 for the same period of fiscal '20. Consolidated net income for the 6 months ending October 31, 2020, was $67,000 or $0.01 per diluted share compared to a net loss of $5.5 million or $0.61 per diluted share in the previous year.
Our fully funded backlog at the end of October 2020 was approximately $42 million, up approximately $6 million from the previous year-end April 30, 2020. The company's balance sheet continues to reflect a strong working capital position of approximately $40 million at October 31, 2020, and a current ratio of approximately 4.5:1. The company believes that its liquidity is adequate to meet its operating and investing needs for the next 12 months and the foreseeable future.
I will turn the call back to Stan, and we look forward to your questions later.